CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME
September 26, 2020
Connecta Therapeutics has closed a €1.7million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have fragile X syndrome (FXS). CDTI and the biotechnology company’s founders also participated.